欧盟HMA上市药品数据库提供Lorazepam Medopharm 2,5 mg药品的基本信息,包括通用名lorazepam,中文名劳拉西泮,ATC代码N05BA06 lorazepam以及上市许可持有人Medochemie Bohemia Lehárova 1808/11, Praha 4 Modřany, 14300, Czech Republic等信息的查询.
1To evaluate the effect of end-stage renal insufficiency and haemodialysis on the elimination of lorazepam, single oral doses of the drug (2.5 mg) were administered to normal subjects and patients with chronic renal failure (Ccr: less than 2 ml/min) in the interdialysis period and during ...
Lorazepam Related Compound B (25 mg) (2-Amino-2',5-dichlorobenzophenone),劳拉西泮有关物质B,2958-36-3,供应厂家CATO标准品。提供标准品,对照品价格等详细信息:
or 2.5 mg. lorazepam 2- to 3-times daily, or with 5 mg. or 12.5 mg. diazepam 2- to 3-times daily for a period of 10 days. Dosage levels were determined by the initial severity of symptoms. After a wash-out period of 5 days on placebo, patients were then crossed over on ...
The average dosage range was 0.5 to 5 mg. lorazepam t.d.s. The highest daily dose was 30 mg.; the longest duration of treatment almost 2 years. Distinct improvement in symptoms such as anxiety, restlessness, agitation, tension, irritability and insomnia has been noted in about 70% of ...
LZP [2 mg, intravenous (i.v.) bolus] was administered to 8 normal volunteers before and after chronic dosing with VPA. In 6 of 8 subjects, VPA significantly decreased LZP plasma clearance by an average of 40% (p < 0.05) and increased LZP concentrations by decreasing formation clearance of...
We studied the effects of 1 week's administration with lorazepam (2 mg daily, PO) or placebo on striatal D[sub 2] dopamine receptors in four healthy male volunteers using a double-blind randomized cross-over design. D[sub 2] receptor density and affinity as well as binding potential (B[...
2. In Experiment 1, rats were injected with diazepam (5 mg/kg), buspirone (1.5 mg/kg or .75 mg/kg), or saline shortly before each of 12 bar press training sessions. Injections were suspended and three days later the rats received five days of Pavlovian fear conditioning (bars removed)...
METHODS: Twenty-four healthy subjects were enrolled and grouped into UGT2B15*1/*1 or UGT2B15*2/*2 genotype groups. The pharmacokinetic and pharmacodynamic profiles of intravenous lorazepam were characterized before and after inhibition with 600 mg valproate once daily for 4 days and after ...
lorazepam 2- to 3-times daily, or with 5 mg. or 12.5 mg. diazepam 2- to 3-times daily for a period of 10 days. Dosage levels were determined by the initial severity of symptoms. After a wash-out period of 5 days on placebo, patients were then crossed over on comparable ...